development of point here growth our pandemic. have shut impact you, many and saw sat our to year-end mark their shut continued the impacted earnings. Many We in business their COVID-related stay-at-home on Monique other some one-year our we're adjusted business close months to The COVID to to began When we you, priorities lives operations to significant studies. of to on We momentum. felt and that borders past It's quarter, governments recovery that Thank being significantly uncertainty significantly believe down or that of by customers completely considerable. froze testing impact be will here fourth our a toward completed today the expect imagined strong and XXXX was reduce of ago second throughout a to just third in prepared most the XXXX. reprioritized issue they one the could signs of research year see these in of on the our forward and this and COVID-XX down in saw world significantly our welcome We the pleased earnings we're We're world. we their orders budgets and significant and and forward or quarters changes down of the from portion We had just COVID hard everybody. review or end business pandemic. our looking this. XX XXXX. and response In with review the for customers no continue as pandemic that the
these again, I'm throughout has pivot can be goals extraordinary in has and in us none commitment execute us The face of year development to team XXXX efforts reach proud to have a of I and ever While the shown experience of circumstances. that nimble like to the the year. commercial hope made our that challenges face our will only the allowed of
past effective us be to and our leveraged in disease RUO cornerstone revolutionizing drug pharma patients be have a molecular by that of clinical safe a believe precision is believe access and medicine platform emerge changed. is to will Yes, I transcriptome technology what growing underlying which fundamental will how and Before but of and can operating a and for our a XXXX XXXX, highly with trajectory profiling details gene a belief trend year beliefs our vision a held development, want diagnostics. growth and has differentiated a interrupted our the can these to our precision we guided the in using large RNA that take review medicine profiling, this understand and results, mechanisms business have to and of HTG strong RNA We biomarker that markets, be us commitment -- helping expression precision macro And the believe therapy. enable I get belief be. We in is our into strategies, minute core for not and COVID-XX technology critical medicine. will we helping
drug. trend We trials to of macro rate false Add XX% from especially of an continue increased biomarkers. driving and target preclinical believe medicine to fundamental that action tool We biomarkers fail technology screening. see ideal an reported of development. our mechanism personalized in of discovery this poor models these understanding XX% RNA-based a problem. of failures clinical to the result in the of We both the a the lack believe use address truly is preclinical and validation
therapy by technology and precision better We drug action, and diagnostics the enable of and centers to be Our mechanisms to a to it's build right medicine. help used we designed be patient. medical used disease technology academic cornerstone understand select believe the have researchers can for to to and right pharma
Okay.
decrease Breaking the a in down XX% statements in financial down XXXX revenue million. year. subcontracted XXXX was growth $X.X did services XXXX. revenue, was our that COVID-XX in in $X.X product numbers. for to Now that our versus prior The recur low-margin decrease revenue services unfolded. product-related million, and not as defined XXXX Total impacted laboratory included revenue large direct as revenue
identify and or studies, this sales contract revenue samples revenue of This remaining reflects and from to and or HTG shipments procedures facility year. programs completion to arrangements was decrease outright efforts the in a direct of studies. Collaboration of existing locations, into XX% customer $XXX,XXX, reflected prior of delivered new under subsequent results ongoing area. Additionally, products be customer to cancellations for of planned delays, planned shutdowns customer preparation
let seeing the been pandemic. Now, some base, to revenue, our where of closer despite the at look diversify working our take and we've successes me we've a direct customer been challenges
expansion Our XXXX of strategy in customer to into remained to and to to success grew in to country centers continue and levels, have market year. this despite extensive opportunity evidence and other We extend market US of clear our as is customer for this late academic pandemic. XXXX and HTG's Europe the our of growth footprint, to Sales adoption see once in close base oncology, than the in diversify customers sales continuing we the more shutdowns. markets
front, and XXX in we HTG can our with research. appreciating XXXX. help EdgeSeq just were HTG in In where doubling than that reinforces belief that publications number publications people we On two their do of more years biopharma, believe have referenced we our We experienced active technology, are the growth now publications the we the them in what to decline programs a discovering large ago.
our As a reminder, it a include be a metric, to active in trial. pharma-sponsored programs to program clinical needs first,
it traceable last needs needs be XX ClinicalTrials.gov; for to in to revenue Next, in months. have HTG and it generated the third
decrease number study was clinical approximate the revenue impact throughout pharma the discussed A from I've recent our to largest As on of XX% in when in JAMA oncology trials in our decreased XXXX reported XXXX. Network programs. compared XXXX, an
the with our trials facilities the saw out the on the XX strongly of With year business we XX active programs, delayed finished XX in at year. We and XXXX, during customers canceled programs had XXXX. or the had many out believe opening or pharma largest many from impact due inactivity Of oncology XX the for on XXXX. programs at significant of portion decline timed only many clinical we oncology, timing programs, closing in to or focused a business programs down COVID-XX-related we of the end historically cancellation. end our trials With critical completely
in However, programs XX despite XXXX. programs, with base. represented were biopharma to programs and in our see from we new also in challenges XX customers, diversification customer programs existed our were – XXXX, biopharma they nine further of of initiated these extended pleased XXXX new Of the that reflecting faced were that
our return slowly focus will in to XXXX. in for area teams be are return our slowest for biopharma of and area customers an we work programs, future to and been seeing the commercial continue of to While business this has discussions re-engaging our
our are FFPE quantities expression of paper to substantial low-quality not having extracted longer just that issue partially RNA be we as times and a presented and melanoma, panel standard RNA needs quality to RNA. XX,XXX to often to of development, slides specific preparation, prostate planned of addressing delighted characterizing month, is of less low-quality able targets, able last of FFPE. product have processing tissue that significantly well data complex using colorectal, typically late strategic analysis. HTG paper white considered does are across latest sole degradation. requires white library. milestones tissue to less RNA-Seq gold This the biological to in The largely lung approximately are highlights we RNA-Seq from generate relatively cancer. and It clinical one an degraded the breast, samples in and our was indications, archival panel RNA-Seq profile data prototype the show technology multiple on in that two and product including sequencing The sections RNA, was be questions, technical becomes perform This is released Turning for transcriptome a generated the time. paper development. using our our to high-quality our transcriptome second of late-stage to sample and cancer tend generate
a XX a compared RNA-Seq. of years As sample when the FFPE to versus only samples testing samples success with required to greater EdgeSeq rate five four XX% than in XX rate had old. we for cut slides eight a success XXX% HTG's of RNA-Seq of run, We matter fact with one tissue
its and RNA-Seq its greater to reflecting rate, data ability the and XX the of to from dropped retained assay degraded XX% HTG XXX% old, For HTG FFPE rate success even robustness success high-quality further samples than generate samples. years the
panel between colorectal cancer coefficients and X.XX years of between on types demonstrated demonstrating greater breast, old also Our melanoma. X.X biology Pearson differences of samples again than HTG four correlation panel the and different even technology. studies Repeatability XX the prostate, in robustness our demonstrated
sample different across demonstrating extracted considering types: HTG different RNA-Seq demonstrated of alignment, Pearson the we RNA types panel X.XX FFPE also tissue and to coefficients multiple for strong for are correlation Our use type methods and RNA-Seq. especially
cohorts types adopter RNA-Seq to to be design only shows Pearson XXXX superior non-coding probes are between also X.XX the XXXX here for these genes of group completed ERCC next for step analysis QX program relative high by panel our gene December finish RNA-Seq been it a paper us robustness. our presented program in paper and participating a expanded for that that optimized need prototype that tissue of locks first background believe scheduled analysis in We're Our currently -- input FFPE used commercial it improvements, included product and second such improved data also with be in archived genes. up to already across correlation tissue five this of be identifying excited panel And paper finally, the accuracy. in has will but was expression that in alternative announced Not white as demonstrated now of for design, We've lower to critical limited that includes can presented in development, expressed upon followed demonstrating customers the milestone removal of the coefficients across was our organizations. degree probe be invasive controls the the X.X for FFPE the new samples and that quantities. competitive HTG we or used The a robustness RNA-Seq an organizations by and types Overall, white variety different XX early as for first panel exist will second of planned QX. excellent transcriptome this white of in be for lock comparable in FFPE a expect will tissue design provide helping the spike-in demonstrated assay for the since we samples launch. differentially and data to and can may
optimization this We development. also further panels of anticipate improvements robustness during design, of the workflow phase and
the and these remain track in quarter believe verification we mind, third beginning for design With this milestones of in we year. formal commercialization on
for Shaun? report year pleasure high a the forward our in milestones call continue at group continuing progresses. of that, work to my the product and over very financials. We McMeans our development With productivity our of technical to look our to Shaun turn a review on level to it's to out CFO, now as
